Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients

The effect of switching from originator infliximab to biosimilar infliximab in patients with sarcoidosis is unknown. The objective of this study is to investigate the effect of switching from Remicade(®) or Inflectra(®) to Flixabi(®) in patients with severe refractory sarcoidosis. This single center...

Descripción completa

Detalles Bibliográficos
Autores principales: Peters, Bas J. M., Bhatoe, Anish, Vorselaars, Adriane D. M., Veltkamp, Marcel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922542/
https://www.ncbi.nlm.nih.gov/pubmed/33669641
http://dx.doi.org/10.3390/cells10020441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922542/
https://www.ncbi.nlm.nih.gov/pubmed/33669641
http://dx.doi.org/10.3390/cells10020441

Ejemplares similares